Member Info for liquid1

Double digits tomorrow

https://www.researchgate.net/publication/339592997_NADS_in_COVID-19_-_short_communication_-_version_11_-_15_A4_pages_without_references_-_31032020_Potent_NRF2-activating_dietary_supplements_like_resveratrol_curcumin_sulforaphane_Asea_redox_supplement_

While the COVID-19 (Coronavirus) pandemic has been a source of instability and stress beyond our collective imagination, Belluscura’s entire team, research partners and regulatory and manufacturing consultants are diligently working together to soon bring the X-PLO2R portable oxygen concentrator to the market. We will announce publicly when the X-PLO2R receives 510(K) clearance from the US Food and Drug Administration.

The Belluscura team wishes you and your loved ones good health. Please continue to follow the authorities' recommendations for social distancing and the regular washing of your hands.

Speeding ticket!

Damn shame.. over to TEK now

Hit 86p!

Will close nearer 80p!
Still cheap!

NMC Health could turn to market for cash

Monday April 13 2020, 12.01am, The Times

The administrator of NMC Health has raised the prospect of returning to the stock market to fund the troubled hospitals company’s rescue.

Last week Alvarez & Marsal was appointed after an application to the High Court by Abu Dhabi Commercial Bank, one of NMC’s biggest creditors with an exposure of almost $1 billion.

Court documents show that Alvarez & Marsal believes that if a restructuring of NMC “is achievable, it may be desirable to continue to make use of the company as a listed entity to allow the group access to equity funding”.

https://www.prnewswire.co.uk/news-releases/lamellar-biomedical-launches-program-designed-to-prevent-the-severe-respiratory-effects-of-covid-19-using-its-unique-lamellasome-tm-technology-894472742.html

https://www.investegate.co.uk/motif-bio-plc--mtfb-/rns/motif-signs-agreement-with-lamellar-biomedical/201905010700146567X/

https://apnews.com/a6e4bd5f8aafece763c28dfc69b25b5e

https://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-using

01 May 2019, 08:31Source - SMW
Motif Bio said it had signed an agreement with Lamellar Biomedical under which the companies would investigate a combination of their offerings.

The arrangement would see Motif Bio conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar's patented technology.

Iclaprim had been granted US orphan drug designation for staphylococcus aureus pneumonia in patients with cystic fibrosis.

----------------------------------------------------------------------

Lamellar Biomedical says lung treatment could save lives of Covid-19 patients
Lanarkshire life sciences firm's drug can halt inflammation at early stage of disease

SHARE
BY HAMISH BURNS
10:15, 8 APR 2020UPDATED10:18, 8 APR 2020
0_Lamellar-KTP-awards.jpg
Some of the Lamellar Biomedical team
Lanarkshire firm Lamellar Biomedical says one of its treatments could help save lives by halting progression of lung damage in Covid-19 patients.

The company has pre-clinical evidence that Lamellasome can protect lung cells and tissue if inhaled within five to eight days of symptoms of respiratory lung disease.

It says early intervention can prevent the Acute Respiratory Distress Syndrome (ARDS) seen in coronavirus patients.

Lamellar chairman Dr Duncan Moore said: “In the past few weeks we have seen the terrible consequences Covid-19 can have on the respiratory function, particularly on vulnerable patient population

anslow11 Apr '20 - 07:36 - 4439 of 4440
0 0 0
Lamellar Bio - hmm I wonder

https://www.sharesmagazine.co.uk/news/market/6406542/Motif-Bio-forms-treatment-cooperation-pact-with-Lamellar-Biomedical

https://www.insider.co.uk/news/lamellar-biomedical-says-lung-treatment-21832806.amp

Hope you’re right!
Who knows?

https://jewishnews.timesofisrael.com/why-israeli-companies-head-for-london/

“Randomized, Double-Blind, Multicenter Phase II Study to Evaluate Efficacy and Safety of Intravenous Iclaprim versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed Caused by Gram-positive Pathogens.”
This poster presented data on outcomes related to treatment with iclaprim compared to vancomycin, a standard of care treatment for Hospital-acquired bacterial pneumonia (HABP), ventilator-associated pneumonia (VAP) and healthcare-associated pneumonia (HCAP).
Patients who received a low dose of iclaprim, a high dose of iclaprim, and vancomycin had a clinical cure rate of 73.9%, 62.5%, and 52.2%, respectively. Under the same treatment regime patients had a Day 28 mortality rate of 8.7%, 12.5%, and 21.7%, respectively.
These data show that iclaprim had high clinical cure rates and relatively low mortality rates among patients with HABP, VAP, and HCAP.

https://www.motifbio.com/news/announces-results-of-two-posters-on-iclaprim-at-id-week-2015/

The Company also has plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication.

https://www.globenewswire.com/news-release/2019/06/24/1872724/0/en/Motif-Bio-Presents-New-Iclaprim-Data-at-ASM-Microbe-2019.html

Trials are currently ongoing for the treatment of ventilator-associated and healthcare-associated pneumonia. Iclaprim is a promising antimicrobial agent for the treatment of gram-positive organisms, including resistant S. aureus and trimethoprim-, macrolide-, fluoroquinolone-, and glycopeptide-resistant strains. Additionally, in vitro activity similar to that of trimethoprim has been observed against gram-negative and atypical organisms.

https://www.researchgate.net/publication/24421392_Iclaprim_a_Novel_Diaminopyrimidine_for_the_Treatment_of_Resistant_Gram-Positive_Infections

Last placing was 0.42p

Maybe see that on Tuesday, unless there a reverse takeover, than much higher!

Cost between 2k to 2.5k each!

Roll on FDA approval

10:32:30 26.997 400,226 108.05k

& Another 100k buy

10:29:52
26.711
372,486
99.50k

03:22 am CST 09/04/2020

Brent Crude
34.02 +3.59%

10:17:52
26.468
375,928
99.50k O